ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2025
A comparison of diagnostic and therapeutic approaches for Mycoplasma pneumoniae pneumonia in children and adults, during the post-COVID-19 pandemic era.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Study on the value and mechanism of miR-369-5p in childhood pneumonia.BMC immunology · 2026Article
- Comparing differences in onset and clinical manifestations between children and adults withFrontiers in public health · 2026Article
- The Expression Levels and Clinical Significance of CARDS TX, MyD88, and IL-8 of Children With Severe Mycoplasma pneumoniae Pneumonia.Mediators of inflammation · 2026Article
- Explainable machine learning for diagnosing severeFrontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesPost-COVID-19, the increasing incidence of adult Mycoplasma pneumoniae pneumonia (MPP) necessitates attention, as it remains understudied due to its low incidence and undefined severity criteria. Therefore, exploring the characteristics of adult MPP and child MPP in terms of clinical diagnosis, treatment, and prognosis is of significant clinical importance. This study investigated the clinical features, severe risk factors, treatment, and prognosis of MPP in children and adults in Hebei, China, following the lifting of COVID-19 lockdown measures, offering insights for the diagnosis and treatment of MPP across age groups.
methodsFrom May 2023 to March 2024, a total of 218 hospitalized MPP patients at the First Hospital of Hebei Medical University were enrolled, with children (≤ 14 years) and adults (≥ 18 years) randomly selected at a 1:1 ratio (109 children and 109 adults). Patient demographics and clinical data were recorded and analyzed to compare the diagnostic and treatment profiles of pediatric and adult MPP patients.
resultsThis study revealed that among 218 MPP patients, adult MPP patients differ significantly from child MPP patients in terms of clinical symptoms, the inflammatory response, coagulation status, and organ damage. In addition, C-reactive protein (CRP) (OR, 1.073; 95% CI, 1.032-1.116; P < 0.001) was a severe risk factor for adult MPP, whereas CRP, aspartate transaminase, and potassium (OR: 1.209, 1.124, 31.322; 95% CI: 1.072-1.362, 1.016-1.244, 3.112-315.213; P = 0.008, 0.02, 0.003) were positively associated with the severity of MPP in children. Interestingly, children and adults with MPP received different treatments, and adult MPP patients had shorter hospital stays but poorer lung infection resolution. The positive detection rate of macrolide-resistance genes was 70.8% (34/48). Compared with the macrolide-resistance MPP (MRMPP) subgroup in children (treated with macrolides), the MRMPP subgroup in adults (treated with quinolones) had shorter hospital stays and higher rates of improvement in lung infection (P < 0.05), and the recovery of eosinophil percentage, white blood cell count, neutrophil count and platelet-lymphocyte ratio was better.
conclusionIn short, adult and child MPPs differ significantly in terms of clinical diagnosis, treatment, and prognosis. Early intervention for severe risk factors, monitoring MR genes and managing macrolides can lead to improved prognosis.
Indexed as
Identifiers
40299295What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.